A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Journal of Medicinal Chemistry · 22.08.2024 · 67 (16) · 13550-13571
DOI: 10.1021/acs.jmedchem.3c02469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.04.2024. Verfasst von Charlotte M N Allerton und 46 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Research & Development, Cambridge, Massachusetts 02139, United States. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, SARS-CoV-2, Antiviral Agents, Protease Inhibitors. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States.
- Pfizer Research & Development, Groton, Connecticut 06340, United States.
- Pfizer Research & Development, Pearl River, New York 10965, United States.
- Pfizer Research & Development, La Jolla, California 92121, United States.
- Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah 84322, United States.
ORCID-Profile: Britton Boras, Li Di, Kathleen A Farley, Amit S Kalgutkar, Emi Kimoto, Dafydd R Owen, Nandini C Patel, Matthew F Sammons, Qingyi Yang
Zitieren
APA
Allerton, C. M. N., Arcari, J. T., Aschenbrenner, L. M., Avery, M., Bechle, B. M., Behzadi, M. A., Boras, B., Buzon, L. M., Cardin, R. D., Catlin, N. R., Carlo, A. A., Coffman, K. J., Dantonio, A., Di, L., Eng, H., Farley, K. A., Ferre, R. A., Gernhardt, S. S., Gibson, S. A., …, & Zhu, Y. (2024). A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19. Journal of Medicinal Chemistry, 67(16), 13550-13571. https://doi.org/10.1021/acs.jmedchem.3c02469
Vancouver
Allerton CMN, Arcari JT, Aschenbrenner LM, Avery M, Bechle BM, Behzadi MA, et al. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19. Journal of Medicinal Chemistry. 2024;67(16):13550-13571. doi:10.1021/acs.jmedchem.3c02469
BibTeX
@article{Allerton2024,
author = {Allerton, Charlotte M N and Arcari, Joel T and Aschenbrenner, Lisa M and Avery, Melissa and Bechle, Bruce M and Behzadi, Mohammad Amin and Boras, Britton and Buzon, Leanne M and Cardin, Rhonda D and Catlin, Natasha R and Carlo, Anthony A and Coffman, Karen J and Dantonio, Alyssa and Di, Li and Eng, Heather and Farley, Kathleen A and Ferre, Rose Ann and Gernhardt, Steven S and Gibson, Scott A and Greasley, Samantha E and Greenfield, Siennah R and Hurst, Brett L and Kalgutkar, Amit S and Kimoto, Emi and Lanyon, Lorraine F and Lovett, Gabrielle H and Lian, Yajing and Liu, Wei and Martínez Alsina, Luis A and Noell, Stephen and Obach, R Scott and Owen, Dafydd R and Patel, Nandini C and Rai, Devendra K and Reese, Matthew R and Rothan, Hussin A and Sakata, Sylvie and Sammons, Matthew F and Sathish, Jean G and Sharma, Raman and Steppan, Claire M and Tuttle, Jamison B and Verhoest, Patrick R and Wei, Liuqing and Yang, Qingyi and Yurgelonis, Irina and Zhu, Yuao},
title = {A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {16},
pages = {13550--13571},
doi = {10.1021/acs.jmedchem.3c02469}
}
EUVIMED